Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 4 days ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 14 days ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 8 months ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 10 months ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - 11 months ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - 11 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 11 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - about 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - about 1 year ago
2	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 7 days ago
3	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 7 days ago
4	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 7 days ago
5	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	2024 PharmaVoice 100s: Rare Disease Warriors - 17 days ago 2024 PharmaVoice 100s: Patient Champions - 24 days ago 2024 PharmaVoice 100s: Trailblazers - 30 days ago 2024 PharmaVoice 100s: Standout Leaders - about 1 month ago Who’s winning in biotech’s tight market? - 2 months ago What 3 layoff stories reveal about pharma’s troubles - 2 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 5 months ago Where competition is heating up in pharma - 6 months ago 3 big recent trial flops - 7 months ago The biggest questions hanging over pharma in 2024 - 10 months ago Pharma execs sound off on trends and policies they’re tracking in 2024 - 10 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - 10 months ago 10 of our most read articles in 2023 - 11 months ago PharmaVoice 100s: Entrepreneurs - about 1 year ago PharmaVoice 100s: Clinical trial gurus - about 1 year ago 3 recent FDA adcomm rejections — and why they matter - about 1 year ago The PharmaVoice 100: Standout execs - about 1 year ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	3 FDA approval dates to watch in the year’s final push - 2 months ago Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision - 3 months ago Pharma execs react to final drug price negotiations with Medicare - 3 months ago Read to lead: 6 books pharma execs swear by - 4 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 4 months ago Behind Big Pharma’s layoffs — is there an end in sight? - 5 months ago Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies - 6 months ago 4 offbeat biotechs making a splash in the life sciences - 7 months ago 5 Big Pharma CEOs who saw major pay bumps in 2023 - 8 months ago These biotech hotspots are ripe for IPOs - 8 months ago
7	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - 3 months ago The biotech news you missed this week - 4 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 6 months ago Lawmakers want to add more Chinese biotechs to defense list - 8 months ago
8	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	PBMs battle bipartisan scrutiny as lawmakers eye industry reform - 4 months ago PBMs, PhRMA trade blame over drug costs in House hearing - about 1 year ago
9	Susanna Vogel Healthcare Dive Currently at Healthcare Dive. Seen in various outlets. Greenpoint healthcarejournalism	PBMs battle bipartisan scrutiny as lawmakers eye industry reform - 4 months ago
10	Sydney Halleman Healthcare Dive Reporter/writer. Bad tweeter. Virginia, USA journalism	Latest 340B ruling delivers blow to providers - 6 months ago

Journalists covering BioPharma, Legal, Pharma, Providers